OTCPK:PBBI.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Probi AB (publ), a bioengineering company, researches, develops, manufactures, markets, and sells probiotics for food, health, and pharmaceutical companies.


Snowflake Analysis

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Probi's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PBBI.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.6%

PBBI.F

1.1%

US Biotechs

2.4%

US Market


1 Year Return

-21.2%

PBBI.F

24.7%

US Biotechs

9.2%

US Market

Return vs Industry: PBBI.F underperformed the US Biotechs industry which returned 24.7% over the past year.

Return vs Market: PBBI.F underperformed the US Market which returned 9.2% over the past year.


Shareholder returns

PBBI.FIndustryMarket
7 Day5.6%1.1%2.4%
30 Day95.4%6.8%10.2%
90 Dayn/a10.0%3.4%
1 Year-21.2%-21.2%26.0%24.7%11.6%9.2%
3 Yearn/a34.5%30.1%33.7%24.9%
5 Yearn/a-4.1%-9.8%59.7%41.8%

Price Volatility Vs. Market

How volatile is Probi's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Probi undervalued compared to its fair value and its price relative to the market?

34.69x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PBBI.F ($27.35) is trading above our estimate of fair value ($24.01)

Significantly Below Fair Value: PBBI.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PBBI.F is poor value based on its PE Ratio (34.7x) compared to the Biotechs industry average (18.2x).

PE vs Market: PBBI.F is poor value based on its PE Ratio (34.7x) compared to the US market (16.1x).


Price to Earnings Growth Ratio

PEG Ratio: PBBI.F is poor value based on its PEG Ratio (1.5x)


Price to Book Ratio

PB vs Industry: PBBI.F is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Probi forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

23.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PBBI.F's forecast earnings growth (23.7% per year) is above the savings rate (2.2%).

Earnings vs Market: PBBI.F's earnings (23.7% per year) are forecast to grow faster than the US market (22.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PBBI.F's revenue (7.4% per year) is forecast to grow slower than the US market (8.8% per year).

High Growth Revenue: PBBI.F's revenue (7.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PBBI.F's Return on Equity is forecast to be low in 3 years time (9.8%).


Next Steps

Past Performance

How has Probi performed over the past 5 years?

8.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PBBI.F has high quality earnings.

Growing Profit Margin: PBBI.F's current net profit margins (13.6%) are higher than last year (13.1%).


Past Earnings Growth Analysis

Earnings Trend: PBBI.F's earnings have grown by 8.3% per year over the past 5 years.

Accelerating Growth: PBBI.F's earnings growth over the past year (7.9%) is below its 5-year average (8.3% per year).

Earnings vs Industry: PBBI.F earnings growth over the past year (7.9%) exceeded the Biotechs industry -4.5%.


Return on Equity

High ROE: PBBI.F's Return on Equity (7.1%) is considered low.


Next Steps

Financial Health

How is Probi's financial position?


Financial Position Analysis

Short Term Liabilities: PBBI.F's short term assets (SEK403.2M) exceed its short term liabilities (SEK80.1M).

Long Term Liabilities: PBBI.F's short term assets (SEK403.2M) exceed its long term liabilities (SEK52.5M).


Debt to Equity History and Analysis

Debt Level: PBBI.F is debt free.

Reducing Debt: PBBI.F had no debt 5 years ago.

Debt Coverage: PBBI.F has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: PBBI.F has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Probi's current dividend yield, its reliability and sustainability?

0.37%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PBBI.F's dividend (0.37%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.65%).

High Dividend: PBBI.F's dividend (0.37%) is low compared to the top 25% of dividend payers in the US market (4.39%).


Stability and Growth of Payments

Stable Dividend: PBBI.F is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: PBBI.F is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: PBBI.F is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PBBI.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Tom Rönnlund (47yo)

1.42yrs

Tenure

kr3,974,000

Compensation

Mr. Tom Rönnlund is Chief Executive Officer at Probi AB (publ) since January 1, 2019. Mr. Rönnlund was the Chief Executive Officer of Navamedic ASA from May 18, 2015 to December 31,2018. Mr. Rönnlund has m ...


CEO Compensation Analysis

Compensation vs Market: Tom's total compensation ($USD428.85K) is below average for companies of similar size in the US market ($USD2.17M).

Compensation vs Earnings: Insufficient data to compare Tom's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Tom Rönnlund
Chief Executive Officer1.42yrskr3.97m0.012% SEK40.5k
Henrik Lundkvist
Chief Financial Officer1.42yrsno data0.0013% SEK4.3k
Andy McShea
Vice President of Global Operations1.67yrsno datano data
Niklas Larsson
Lead Scientific Affairs1.67yrsno datano data
Shane Judge
Global Vice President of Sales & Marketing0.42yrno datano data
Basudha Bhattarai-Johansson
Vice President of Human Relations0.42yrno datano data
Anna-Karin Robertson
Head of Discoveryno datano datano data
Magdolna Dimén
Group Controllerno datano datano data

1.4yrs

Average Tenure

48yo

Average Age

Experienced Management: PBBI.F's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Hans Wigzell
Member of Scientific Advisory Boardno datano datano data
Lars Gatenbeck
Member of Scientific Advisory Boardno datano datano data
Charlotte Hansson
Independent Director3.08yrskr330.00k0.0044% SEK14.5k
Jan Nilsson
Chairman of Scientific Advisory Boardno datakr55.00kno data
Jean-Yves Parisot
Chairman of the Board5.17yrskr505.00kno data
Jörn Andreas
Director1.08yrskr225.00kno data
Glenn Gibson
Member of Scientific Advisory Boardno datano datano data
Maria Rescigno
Member of Scientific Advisory Boardno datano datano data
Henrik Vestergaard
Member of Scientific Advisory Boardno datano datano data
Irène Malnoë
Independent Director2.08yrskr238.00kno data

2.6yrs

Average Tenure

59yo

Average Age

Experienced Board: PBBI.F's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PBBI.F insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Probi AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Probi AB (publ)
  • Ticker: PBBI.F
  • Exchange: OTCPK
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr3.054b
  • Listing Market Cap: kr329.526m
  • Shares outstanding: 11.39m
  • Website: https://www.probi.com

Number of Employees


Location

  • Probi AB (publ)
  • Sölvegatan 41A
  • Lund
  • Skåne County
  • 223 70
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PROBOM (OMX Nordic Exchange Stockholm)YesCommon SharesSESEKNov 2004
0GZBLSE (London Stock Exchange)YesCommon SharesGBSEKNov 2004
PROBSBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBSEKNov 2004
PBBI.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2004

Biography

Probi AB (publ), a bioengineering company, researches, develops, manufactures, markets, and sells probiotics for food, health, and pharmaceutical companies. The company operates in two segments, Consumer Healthcare and Functional Food. It conducts research primarily in the fields of digestive health, immune response, and nutrient absorption. The company provides dietary supplement, and food and beverage products in the form of powder, capsules, tablets, and fruit juice drinks. It sells its products in approximately 40 countries worldwide. Probi AB (publ) has a development agreement with Cilag GmbH International for the development of probiotic products. The company was founded in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) operates as a subsidiary of Symrise AG. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/04 06:10
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.